Biomarkers and complex clinical assays are recognized as essential tools for the development of therapeutics, allowing improved and better-informed clinical trial design through indicators of target engagement and those that enable patient stratification. Our Team can help design and validate new assays in our CAP/CLIA laboratory, undertake method transfers or migration modification of existing novel methods.
Our expert Board-certified pathologist and PhD scientific teams are on hand to provide protocol consulting, Biomarker selection / consultation, Biomarker assay development, Companion diagnostic selection / validation, access to pathology tissue and biobank resource, and support all aspects of your Phase I, II, III specialty laboratory testing.
IVD/CDx Study Support
Our Expertise in CAP/CLIA molecular diagnostics, pathology, informatics, innovative solutions, and technologies makes us an ideal choice to meet your IVD/CDx testing needs. We have over two decades of experience with major instrument and diagnostic reagent manufacturers in providing support for IVD/CDx studies. Our services include.
Assay validation for 510K/PMA data collection
Presentation of data to the FDA Advisory Committee
Partner for Companion Diagnostic Development
Platform and Assay Correlation
Clinical Interpretive Expertise and Result Consultation
We use cookies to enhance your browsing experience; by continuing to use this site, you consent to the use of cookies in accordance with our privacy policy.AgreePrivacy policy